Why is Boston Scientific stock sliding today?

Boston Scientific fell 3.6% to $43.42 in premarket trading after Q3 adjusted EPS of $0.73 missed the $0.75 consensus, despite revenue of $5.14 billion slightly topping estimates and growing 1.5% year over year. The company cut full-year 2026 adjusted EPS guidance to $3.16–$3.18 from $3.28–$3.32 and forecast Q4 sales to decline 1%–3% year over year. Management cited lingering disruption from an August 25 cyberattack, alongside competitive pressure and softer WATCHMAN demand; the stock was near its 52-week low of $41.38.

Analysis

The key distinction is temporary fulfillment disruption versus a deterioration in the earnings engine. The cut makes near-term estimate revisions likely, but it does not by itself establish lasting demand loss: procedures and orders may be deferred, while competitors can convert disruption into durable share only if clinicians or hospitals switch rather than wait. That risk is more consequential where Boston Scientific already faces competitive pressure in electrophysiology and softer demand in structural heart. Abbott Laboratories, Johnson & Johnson, and Medtronic are potential beneficiaries if switching occurs, though product-level share data are needed to confirm it.

Over the next several weeks, operational uncertainty and lower earnings estimates can keep BSX pressured; proximity to the 52-week low raises the chance of a sharp relief rally if shipment recovery is faster than feared. Over 1–3 months, watch order backlog, shipment conversion, procedure trends, and whether management restores visibility. Over 6–18 months, sustained share loss would matter more than a one-quarter disruption because it would weaken the growth multiple. The contrarian case is that investors may conflate delayed sales with lost sales, but existing franchise-specific headwinds make a full snapback an unsafe base case. Falsification of the bearish thesis: clear evidence of backlog conversion, restored guidance, and stable product-level share; evidence of persistent cancellations or further guidance cuts would reinforce it.

Key Decisions for Investors

• Maintain an underweight in BSX versus diversified medtech exposure rather than adding solely because the share price is near its annual low. Reassess after the next operational update; the risk/reward is asymmetric if recovery timing remains unverified.
• For a defined-risk bearish expression, consider a put spread rather than outright puts, subject to checking implied volatility and liquidity. Avoid chasing the premarket decline; elevated event volatility and a fast shipment-recovery update could trigger a sharp rebound.
• Treat a relative-value short BSX / long diversified medtech basket as a watch item, not a high-conviction pair, until product-level data distinguish temporary shipment delays from share loss. Review if backlog conversion improves without further estimate cuts.
• Track factory and shipment normalization, order cancellations versus deferrals, and electrophysiology and WATCHMAN-related demand indicators. A further guidance reduction or evidence of competitor conversion strengthens the bearish case; restored visibility and stable share would invalidate it.